You searched for "patient"
Endoscopic injection of bulking agent for recurrent paediatric epididymitis
Paediatric recurrent epididymitis is frequently observed in several urogenital conditions, and may result in deterioration of long-term fertility. The management of recurrent epididymitis is still a therapeutic challenge for paediatric urologists, and as yet there is no consensus for treatment....
Prostatic artery embolisation versus sham
Randomised trials with use of sham is uncommon in the surgical literature, which makes this paper more interesting. Many different treatments are available for treating lower urinary tract symptoms / benign prostatic hyperplasia (LUTS / BPH). Prostatic artery embolisation (PAE)...
Urinary tuberculosis and the busy urologist!
This article is a very good read for any busy urologist. When in medical school, we were taught that tuberculosis (TB) was rare in the UK and other developed countries. We have come full circle; now there are increasing cases...BBS Revolution™ Bladder Scanner
Featuring a wireless scanning probe with eight ultrasound transducers for fully automatic bladder detection, BBS Revolution™ differentiates between male and female anatomy and delivers accurate volume measurements in seconds.Viveca Biomed acquires Contrelle Activgard – European market launch imminent!
Viveca Biomed is pleased to announce the imminent relaunch of Contrelle Activgard across Europe, starting with the UK market.Manfred Sauer looks forward to seeing you at the BAUN Conference 2022 on STAND 9
We are a manufacturer and supplier of continence care products with a difference. Our products are often designed by patients and healthcare professionals with innovative and unique features and benefits.
PARP inhibitors and prostate cancer
The discovery that BRCA1/2-deficient tumour cells are highly sensitive to poly-ADP ribose polymerase (PARP) inhibitors (PARPi) established the foundation of synthetic lethality in metastatic castration-resistant prostate cancer (mCRPC). The TOPARP-A trial confirmed clinical benefit, with PARPi activity largely restricted to...
